Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We…
SUPERNUS PHARMACEUTICALS, INC. reported results for the 2026 quarter with revenue of $219.06M, up from $165.45M a year earlier, while the company posted a net loss of ($58.37M) and diluted loss per share of ($1.01) versus prior-year net income of $22.5M and EPS of $0.4.Financial Highlights¹ Reporte…
ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. NASDAQ:SUPN, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report second quarter 2026 financial…
